Home › Markets › Health Care › ARDX

Ardelyx Inc. (ARDX)

ARDX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$3.12
-3.41% on the day
Market cap
$777.5M
Small cap
Revenue · 2025
$407.3M
+22.1% on 2024
Net income · 2025
-$62.0M
-15.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerARDX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001437402
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$407.3M
Net income-$62.0M
Operating income-$41.0M
Net margin-15.2%
Operating margin-10.1%
Revenue growth+22.1%
Cash$68.0M
Total assets$501.6M
P/E (computed)Net income was not positive
P/S (computed)1.9×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-11-03
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-08-06
Latest current report8-K2026-08-17
Latest proxyDEFA14A2026-05-26

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.8%
1 month-4.9%
3 months-36.9%
Year to date-44.5%
1 year-35.4%
From 52-week high-59.5%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GERNGeron Corporation$1.20-1.64%$771.0M
HELPHelus Pharma Inc.$10.50-4.80%$767.1M
CRVSCorvus Pharmaceuticals Inc.$9.41-6.37%$791.6M
AVBPArriVent BioPharma Inc.$16.09-2.25%$793.4M
ANLAdlai Nortye Group Ltd.$11.76-17.34%$757.0M
GYREGyre Therapeutics Inc.$6.71-2.26%$748.2M
APMDApnimed Inc.$17.83-4.29%$742.3M
OBXObsidian Therapeutics Inc.$11.99-6.25%$740.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier